MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced it will present two research updates on its investigational drug buntanetap at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases, scheduled for March 17 through March 21 in Copenhagen, Denmark.
The company said the presentations will include clinical data from studies of buntanetap in Parkinson’s disease and an update on its ongoing Phase 3 trial in early-stage Alzheimer’s disease.
One presentation will examine buntanetap treatment in Parkinson’s disease patients with mild cognitive impairment or mild dementia, including biomarker findings related to the therapy’s potential effects.
The second presentation will review the design and progress of a randomized, placebo-controlled, double-blind clinical trial evaluating the safety and efficacy of buntanetap in patients with early Alzheimer’s disease.
Both presentations will be delivered by Cheng Fang, senior vice president of research and development at Annovis Bio.
“We are proud to present the continued progress in enrollment for our Alzheimer’s disease pivotal study, reflecting strong engagement from both investigators and patients,” Fang said.
Fang added that the Parkinson’s disease presentation will include biomarker data that support buntanetap’s therapeutic mechanism.
The AD/PD conference is an international scientific meeting focused on research into neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.